Alberta funding focused on improving treatment of diabetes

June 08, 2016

(Edmonton, AB) The Alberta Diabetes Institute at the University of Alberta has awarded important financial support to another Alberta-based diabetes research project and renewed two projects to continue research that has already shown promising results. The Alberta Diabetes Institute: Johnson & Johnson Diabetes Research Fund is aimed at supporting research in diabetes with a focus on novel discoveries with a high potential for commercialization.

The research fund is a $600,000 partnership between the Alberta Diabetes Institute, Janssen Inc. in Canada (part of the Pharmaceutical Companies of Johnson & Johnson), the Government of Alberta and the Alberta Diabetes Foundation.

"The impact that this research could have, on helping thousands in Alberta manage type 1 and 2 diabetes is incredible," said Brad Fournier, Executive Director -- Alberta Diabetes Foundation. "Each investment must deliver benefit to Albertans and we are confident this will be achieved with these worthy investments."

"Alberta is rapidly becoming a global leader when it comes to diabetes research. By supporting these innovative projects, our government is helping improve the prevention, treatment and management of diabetes. This investment is part of our government's commitment to building a stronger and more diverse economy," said the Honourable Deron Bilous, Minister of Economic Development and Trade.

"This fund represents a unique partnership between Janssen, the Government of Alberta and the Alberta Diabetes Foundation that is directly aimed at transforming great ideas into real-world solutions for people living with diabetes," said Dr. Peter Light, director of the Alberta Diabetes Institute.

In collaboration with the Alberta Diabetes Institute, experts from Johnson & Johnson Innovation identified the high-potential opportunities from projects submitted by medical researchers across Alberta.

The selected fund recipients are:

Selective Angiostatin Neutralization for the Promotion of Therapeutic Angiogenesis in Diabetic Peripheral Artery Disease
Principal Investigator: Dr. Paul Jurasz, University of Alberta

Cuff-Based Electronic Mosquito: A Minimally-Invasive Microsystem for Pseudo-Continuous Monitoring of Glucose Levels in Diabetics (renewal)
Principal Investigator: Dr. Martin P. Mintchev, University of Calgary

Characterization of Islet-Specific ZMIZ1 Knockout Mice (renewal)
Principal Investigator: Dr. Patrick MacDonald, University of Alberta
-end-
For further details on the J&J: ADI Research Fund, please visit http://www.adi.ualberta.ca

More than three million Canadians currently live with diabetes. This private-public partnership fund will accelerate the development of health-care technologies within Alberta, a province known for life-changing research in the causes, prevention, treatment and management of diabetes.

University of Alberta Faculty of Medicine & Dentistry

Related Diabetes Articles from Brightsurf:

Diabetes drug boosts survival in patients with type 2 diabetes and COVID-19 pneumonia
Sitagliptin, a drug to lower blood sugar in type 2 diabetes, also improves survival in diabetic patients hospitalized with COVID-19, suggests a multicenter observational study in Italy.

Making sense of diabetes
Throughout her 38-year nursing career, Laurel Despins has progressed from a bedside nurse to a clinical nurse specialist and has worked in medical, surgical and cardiac intensive care units.

Helping teens with type 1 diabetes improve diabetes control with MyDiaText
Adolescence is a difficult period of development, made more complex for those with Type 1 diabetes mellitus (T1DM).

Diabetes-in-a-dish model uncovers new insights into the cause of type 2 diabetes
Researchers have developed a novel 'disease-in-a-dish' model to study the basic molecular factors that lead to the development of type 2 diabetes, uncovering the potential existence of major signaling defects both inside and outside of the classical insulin signaling cascade, and providing new perspectives on the mechanisms behind insulin resistance in type 2 diabetes and possibly opportunities for the development of novel therapeutics for the disease.

Tele-diabetes to manage new-onset diabetes during COVID-19 pandemic
Two new case studies highlight the use of tele-diabetes to manage new-onset type 1 diabetes in an adult and an infant during the COVID-19 pandemic.

Genetic profile may predict type 2 diabetes risk among women with gestational diabetes
Women who go on to develop type 2 diabetes after having gestational, or pregnancy-related, diabetes are more likely to have particular genetic profiles, suggests an analysis by researchers at the National Institutes of Health and other institutions.

Maternal gestational diabetes linked to diabetes in children
Children and youth of mothers who had gestational diabetes during pregnancy are at increased risk of diabetes themselves, according to new research published in CMAJ (Canadian Medical Association Journal).

Two diabetes medications don't slow progression of type 2 diabetes in youth
In youth with impaired glucose tolerance or recent-onset type 2 diabetes, neither initial treatment with long-acting insulin followed by the drug metformin, nor metformin alone preserved the body's ability to make insulin, according to results published online June 25 in Diabetes Care.

People with diabetes visit the dentist less frequently despite link between diabetes, oral health
Adults with diabetes are less likely to visit the dentist than people with prediabetes or without diabetes, finds a new study led by researchers at NYU Rory Meyers College of Nursing and East Carolina University's Brody School of Medicine.

Diabetes, but not diabetes drug, linked to poor pregnancy outcomes
New research indicates that pregnant women with pre-gestational diabetes who take metformin are at a higher risk for adverse pregnancy outcomes -- such as major birth defects and pregnancy loss -- than the general population, but their increased risk is not due to metformin but diabetes.

Read More: Diabetes News and Diabetes Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.